Search research articles
Contact Us
Filters
Showing results (361-370 of 509) with videos related to
Page
of 51
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 2025
Predicting benefit from PARP inhibitors using deep learning on H&E-stained ovarian cancer slides
Frederik Marmé, Eva I Krieghoff-Henning, Lennard Kiehl, et al.
European Journal of Cancer Care
|
September 7, 2020
Impact of multidisciplinary tumour board in the management of ovarian carcinoma in the first-line setting. Exhaustive analysis from the Rhone-Alpes region
Domenico Ferraioli, Olivia Bally, Pierre Meeus, et al.
Oncotarget
|
August 29, 2015
The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value
Xiaojun Jiang, Daniel Pissaloux, Christelle De La Fouchardiere, et al.
The Oncologist
|
June 24, 2018
Brain Metastases from Adult Sarcoma: Prognostic Factors and Impact of Treatment. A Retrospective Analysis from the French Sarcoma Group (GSF/GETO)
Loïc Chaigneau, Anna Patrikidou, Isabelle Ray-Coquard, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 19, 2013
Primary cardiac sarcomas: a retrospective study of the French Sarcoma Group
Nicolas Isambert, Isabelle Ray-Coquard, Antoine Italiano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 16, 2025
Unravelling the tumor microenvironment and PD-L1 expression across tissue type in high-grade serous ovarian cancer in the NeoPembrOV/GINECO phase II randomized trial
Laetitia Collet, Maude Ardin, David Venet, et al.
Gynecologic Oncology
|
August 15, 2022
Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort
Quentin Dominique Thomas, Amal Boussere, Jean-Marc Classe, et al.
JCO Precision Oncology
|
January 30, 2023
Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial
Eric Pujade-Lauraine, Jessica Brown, Alan Barnicle, et al.
International Journal of Cancer
|
June 28, 2019
Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome-09 study
Sophie Piperno-Neumann, Isabelle Ray-Coquard, Bob-Valéry Occean, et al.
JAMA Network Open
|
November 5, 2025
PARP Inhibitor Maintenance After First-Line Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis
Stamatios Petousis, Ilker Kahramanoglu, Christian Appenzeller-Herzog, et al.
Page
of 51
Search research articles
Search
Showing results (361-370 of 509) with videos related to
Sort By:
Page
of 51
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 2025
Predicting benefit from PARP inhibitors using deep learning on H&E-stained ovarian cancer slides
Frederik Marmé, Eva I Krieghoff-Henning, Lennard Kiehl, et al.
European Journal of Cancer Care
|
September 7, 2020
Impact of multidisciplinary tumour board in the management of ovarian carcinoma in the first-line setting. Exhaustive analysis from the Rhone-Alpes region
Domenico Ferraioli, Olivia Bally, Pierre Meeus, et al.
Oncotarget
|
August 29, 2015
The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value
Xiaojun Jiang, Daniel Pissaloux, Christelle De La Fouchardiere, et al.
The Oncologist
|
June 24, 2018
Brain Metastases from Adult Sarcoma: Prognostic Factors and Impact of Treatment. A Retrospective Analysis from the French Sarcoma Group (GSF/GETO)
Loïc Chaigneau, Anna Patrikidou, Isabelle Ray-Coquard, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 19, 2013
Primary cardiac sarcomas: a retrospective study of the French Sarcoma Group
Nicolas Isambert, Isabelle Ray-Coquard, Antoine Italiano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 16, 2025
Unravelling the tumor microenvironment and PD-L1 expression across tissue type in high-grade serous ovarian cancer in the NeoPembrOV/GINECO phase II randomized trial
Laetitia Collet, Maude Ardin, David Venet, et al.
Gynecologic Oncology
|
August 15, 2022
Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort
Quentin Dominique Thomas, Amal Boussere, Jean-Marc Classe, et al.
JCO Precision Oncology
|
January 30, 2023
Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial
Eric Pujade-Lauraine, Jessica Brown, Alan Barnicle, et al.
International Journal of Cancer
|
June 28, 2019
Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome-09 study
Sophie Piperno-Neumann, Isabelle Ray-Coquard, Bob-Valéry Occean, et al.
JAMA Network Open
|
November 5, 2025
PARP Inhibitor Maintenance After First-Line Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis
Stamatios Petousis, Ilker Kahramanoglu, Christian Appenzeller-Herzog, et al.
Page
of 51